Abstract:Transforming growth factor beta (TGF beta) is a secreted growth and differentiation factor that influences vital cellular processes like proliferation, adhesion, motility, and apoptosis. Regulation of the TGF beta signaling pathway is of key importance to maintain tissue homeostasis. Perturbation of this signaling pathway has been implicated in a plethora of diseases, including cancer. The effect of TGF beta is dependent on cellular context, and TGF beta can perform both anti- and pro-oncogenic roles. TGF beta acts by binding to specific cell surface TGF beta type I and type II transmembrane receptors that are endowed with serine/threonine kinase activity. Upon ligand-induced receptor phosphorylation, SMAD proteins and other intracellular effectors become activated and mediate biological responses. The levels, localization, and function of TGF beta signaling mediators, regulators, and effectors are highly dynamic and regulated by a myriad of post-translational modifications. One such crucial modification is ubiquitination. The ubiquitin modification is also a mechanism by which crosstalk with other signaling pathways is achieved. Crucial effector components of the ubiquitination cascade include the very diverse family of E3 ubiquitin ligases. This review summarizes the diverse roles of E3 ligases that act on TGF beta receptor and intracellular signaling components. E3 ligases regulate TGF beta signaling both positively and negatively by regulating degradation of receptors and various signaling intermediates. We also highlight the function of E3 ligases in connection with TGF beta's dual role during tumorigenesis. We conclude with a perspective on the emerging possibility of defining E3 ligases as drug targets and how they may be used to selectively target TGF beta-induced pro-oncogenic responses.

E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers

ERK/MAPK signalling pathway and tumorigenesis

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

ERK/MAPK Signalling Pathway and Tumorigenesis (Review)

The MAPK Signalling Pathways and Colorectal Cancer

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Regulation of Wnt Signaling through Ubiquitination and Deubiquitination in Cancers

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors

MAPK Signaling in Inflammation-Associated Cancer Development

E3 ubiquitin ligases as cancer targets and biomarkers.

Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases

E3 Ubiquitin Ligases in Cancer and Implications for Therapies

The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer

Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis

E3 Ubiquitin Ligases: Key Regulators of TGF Signaling in Cancer Progression

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression

MAPK/JNK Signalling: a Potential Autophagy Regulation Pathway

The MAPK pathway across different malignancies: A new perspective

MAPK/JNK signaling: A potential autophagy regulation pathway.